Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
IVA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.21
N/A
-0.46
vs -0.32
Q4.21
N/A
-0.76
vs -0.57
Q2.22
N/A
-0.75
vs -0.46
Q4.22
N/A
-0.64
vs -0.76
Q2.23
N/A
-1.43
vs -0.75
Q4.23
N/A
-1.25
vs -0.64
Q2.24
N/A
-1.01
vs -1.43
Q4.24
N/A
-2.69
vs -1.25
Q1.25
N/A
-0.43
vs NA
Q2.25
N/A
-0.67
vs -1.01
Sales Growth
YoY
Current
Estimates
Q2.21
-12%
65K vs 74K
Q4.21
+1822%
4.1M vs 211K
Q2.22
+3%
67K vs 65K
Q4.22
+280%
15.4M vs 4.1M
Q2.23
+9784%
6.6M vs 67K
Q4.23
+7%
16.5M vs 15.4M
Q2.24
-59%
2.7M vs 6.6M
Q4.24
-61%
6.5M vs 16.5M
Q1.25
NA
7.1M vs NA
Q2.25
+46%
4M vs 2.7M
Return on Equity
QoQ
Q2.21
-16%
-0.16
vs -0.16
Q4.21
-30%
-0.30
vs -0.16
Q2.22
-42%
-0.42
vs -0.30
Q4.22
-55%
-0.55
vs -0.42
Q2.23
+721%
7.21
vs -0.55
Q4.23
+172%
1.72
vs 7.21
Q2.24
+62%
0.62
vs 1.72
Q4.24
+127%
1.27
vs 0.62
Institutionnal Ownership
QoQ
Q2.23
7
7
vs 7
NA
Q3.23
6
6
vs 7
-14%
Q4.23
7
7
vs 6
17%
Q1.24
8
8
vs 7
14%
Q2.24
7
7
vs 8
-12%
Q3.24
7
7
vs 7
NA
Q4.24
7
7
vs 7
NA
Q1.25
8
8
vs 7
14%
globenewswire.com
2 hours ago
globenewswire.com
2 hours ago
globenewswire.com
2 hours ago
zacks.com
13 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Forecast
181%2025-Revenue
66%2025-EPS
84%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Societe Generale
upgradePrevious: Not converted
2023-05-19
Now: Buy
Quote Panel
Key Metrics
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
NASDAQ
Unprofitable
Unprofitable
0.07 ( 2.16%)
Pre-market 3.38$
-0.06 (-1.60%)
Relative Strenght
81
Volume Buzz
-59%
Earning Acce
No
Dist 52w H.
15%Relative Strength
IVA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|